Markets

Insider Trading

Hedge Funds

Retirement

Opinion

7 Best Cannabis Stocks to Invest In Now

In this article, we will discuss: 7 Best Cannabis Stocks to Invest In Now. 

Cannabis stocks are ownership stakes in publicly traded businesses engaged in the legal manufacturing, advertising, and distribution of cannabis, marijuana, and hemp-related products.

According to a January 15, 2026, Cannabis Business Times story by David Silverberg, U.S. cannabis operators saw price compression, oversupply, and legislative failures in 2025, which led to margin pressure and a rise in M&A activity. Robert Groesbeck,  co-CEO of Planet 13, the world’s largest cannabis dispensary, brought up Florida’s unsuccessful 2024 ballot and Nevada’s declining tourism. LeVar Thomas of Silly Nice mentioned competition and regulatory costs. University of California, Davis professor Robin Goldstein stressed hemp’s growth and questioned the effects of rescheduling. Abacus Data analysis revealed that 35% of Canadian adults smoked cannabis in the previous six months, while Megan McCrae,  senior vice president, Corporate Strategy & International Growth of Organigram, the cannabis company, stated that international wholesale revenue almost tripled year over year.

Groesbeck’s notes, growth depends on tax and financial policies being clear and transparent. Goldstein cautioned that interstate trade might lead to price competition. Pre-rolls, vapes, and beverages were predicted to gain popularity by McCrae and George Archos.

With that said, here are the 7 Best Cannabis Stocks to Invest In Now.       

Photo by Richard T on Unsplash

Our Methodology

We sifted through the online rankings to form an initial list of the 15 Best Cannabis Stocks to Invest In Now. From the resultant dataset, we chose the 7 Best Cannabis Stocks with the highest number of hedge fund holders for each stock using Insider Monkey’s database of hedge funds as of Q3 2025. We also considered the analysts’ upside potential as of February 10. Finally, we ranked these stocks in ascending order based on hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

7. Organigram Global Inc. (NASDAQ:OGI)

Number of Hedge Fund Holders: 3

Analysts’ Upside Potential as of February 10: 72.59%     

Organigram Global Inc. (NASDAQ:OGI) is among the Best Marijuana Stocks. 

Organigram Global Inc. (NASDAQ:OGI) reported Q1 revenue of $97.3 million, exceeding the $73.15 million consensus, based on a February 10, 2026, TheFly report. Adjusted EBITDA was $5.3 million, up from $1.4 million in the previous year. The corporation reported higher profits and solid revenue growth over the previous year. Higher flower yields, synergies from the Motif integration, more international sales, and operational efficiency all contributed to the adjusted gross margin’s sustained growth. The company anticipates continued international revenue growth in fiscal 2026.

Canaccord began covering the stock on January 27, 2026, with a C$3 price target and a Buy rating. The corporation stated that despite structural inefficiencies and legal obstacles, the Canadian cannabis market continues to be a global benchmark. Organigram Global Inc. (NASDAQ:OGI), the market leader in pre-rolls, extracts, and milled flower, is speeding up its shift to become a globally integrated, vertically integrated cannabis corporation.

Organigram Global Inc. (NASDAQ:OGI) provides high-quality, indoor-grown cannabis to patients and adult recreational customers. It also seeks international business alliances to expand the company’s global presence.

6. Advanced Flower Capital Inc. (NASDAQ:AFCG)

Number of Hedge Fund Holders: 6

Analysts’ Upside Potential as of February 10: 314.75%   

Advanced Flower Capital Inc. (NASDAQ:AFCG) is among the Best Marijuana Stocks. 

TheFly on Jan 05, 2026, stated that, as of January 1, 2026, Advanced Flower Capital Inc. (NASDAQ:AFCG) has successfully converted from a real estate investment trust to a business development company according to the Investment Company Act of 1940. The conversion increases long-term shareholder value by broadening the company’s investment options beyond real estate-backed loans to encompass a wider spectrum of operational enterprises.

In the most recent quarter, Advanced Flower Capital Inc. (NASDAQ:AFCG) recorded a GAAP net loss of $12.5 million, or $0.57 per basic weighted average common share. The amount of $3.5 million in distributable earnings, or $0.16 per basic weighted average common share, was reported. The company stated that it is resolving nonaccrual issues and increasing loan repayments, despite seeing limited new funding enter the cannabis market. Proposals about its plan to change from a REIT to a BDC were accepted by shareholders. It is anticipated that the conversion will be finished in the first quarter of 2026, pending regulatory procedures and customary conditions.

Advanced Flower Capital Inc. (NASDAQ:AFCG) offers commercial real estate financing services. Its main operations include developing, arranging, underwriting, and overseeing senior secured loans as well as other loan types for well-established businesses involved in the cannabis industry in several states.

5. Canopy Growth Corporation (NASDAQ:CGC)

Number of Hedge Fund Holders: 7

Analysts’ Upside Potential as of February 10: 125.57%  

Canopy Growth Corporation (NASDAQ:CGC) is among the Best Marijuana Stocks. 

Alliance Global reduced its price objective on Canopy Growth Corporation (NASDAQ:CGC) from C$2.50 to C$1.80 on February 7, 2026, according to TheFly. It also kept its rating at Neutral after the company’s fiscal third-quarter report. The valuation multiple was lowered by the analyst to account for potential consequences of modifications to veteran reimbursement and the continuous ambiguity around gross margins.

On February 6, 2026, Canopy Growth Corporation (NASDAQ:CGC) announced a fiscal third-quarter loss of C$0.18 per share, down from C$1.11 per share during the same period last year. Revenue rose from C$86.24 million to C$90.39 million in the previous year. According to the corporation, the quarter displayed stronger fundamentals and a more integrated, targeted operating style, with Canada being the strongest area. The management stressed ongoing efforts to improve execution and pointed to the impending acquisition of MTL Cannabis as a chance to gradually fortify the platform even further.

Canopy Growth Corporation (NASDAQ:CGC) produces, sells, and distributes cannabis and products derived from cannabinoids for both medical and recreational use. The company operates in the following segments: Canada Cannabis, International Markets Cannabis, Storz and Bickel, This Works, and Other.

4. Aurora Cannabis Inc. (NASDAQ:ACB)

Number of Hedge Fund Holders: 8

Analysts’ Upside Potential as of February 10: 94.25%  

Aurora Cannabis Inc. (NASDAQ:ACB) is among the Best Marijuana Stocks. 

Based on a Feb. 5, 2026, TheFly report, Canaccord reduced its price target for Aurora Cannabis Inc. (NASDAQ:ACB) from C$10 to C$9. It kept the shares at a Buy rating.

In the third quarter of fiscal 2026, Aurora Cannabis Inc. (NASDAQ:ACB) Cannabis reported a 7% year-over-year growth in total net sales, reaching $94.2 million. Germany and Poland topped the global growth in medical cannabis net sales, which rose 12% to a record $76.2 million. Free cash flow came to $15.5 million, adjusted net income to $7.2 million, and adjusted EBITDA to $18.5 million. The corporation announced a debt-free cannabis business at the conclusion of the quarter, with $154.4 million in cash and short-term investments. The management noted their leadership in genetics, GMP production, global medicinal cannabis, operational efficiency, regulatory knowledge, and prospective M&A possibilities. Chief Executive Officer Miguel Martin remarked that the firm’s results show a concentrated strategy focusing on medical cannabis and trust in its future performance.

Aurora Cannabis Inc. (NASDAQ:ACB) produces, distributes, and sells cannabis and products derived from cannabis. It functions through the Plant Propagation and Cannabis divisions.

3. Village Farms International, Inc. (NASDAQ:VFF)

Number of Hedge Fund Holders: 9

Analysts’ Upside Potential as of February 10: 56.99%  

Village Farms International, Inc. (NASDAQ:VFF) is among the Best Marijuana Stocks. 

On January 12, 2026, TheFly reported that Village Farms International, Inc. (NASDAQ:VFF), through its fully owned subsidiary Leli Holland, has announced the introduction of ten new cannabis product lines in the Netherlands. As per the corporation, the diversified portfolio makes use of consumer insights and operational know-how from legal cannabis marketplaces around the world. The launch places a significant value on competitive distinctiveness, particular consumption occasions, and format innovation. As stated by the company, the products are made with the demands of the Dutch legacy market in mind and show a planned approach to product creation in that market.

Separately, Business in Vancouver announced Village Farms International, Inc. (NASDAQ:VFF) as the 2026 BC Export Awards winner in the Consumer Products category on January 26, 2026. As of September 30, 2025, the company’s export sales had grown by 758% year over year. Exports are supported by EU GMP-certified operations on a 4.8 million square foot production facility that serves highly regulated global medical markets. The business runs major agricultural operations in British Columbia’s Delta.

Village Farms International, Inc. (NASDAQ:VFF) manages and operates agricultural greenhouse facilities across the United States and Canada. Canadian Cannabis, U.S. Cannabis, Produce, Energy, and Leli are its operating segments.

2. Tilray Brands, Inc. (NASDAQ:TLRY)

Number of Hedge Fund Holders: 13

Analysts’ Upside Potential as of February 10: 26.65%  

Tilray Brands, Inc. (NASDAQ:TLRY) is among the Best Marijuana Stocks. 

Canaccord analyst Kenric Tyghe began covering Tilray Brands, Inc. (NASDAQ:TLRY) on January 27, 2026, according to TheFly, with a C$13 price target and a Hold rating. According to the company, despite legislative obstacles and structural inefficiencies, the Canadian cannabis industry continues to set the standard for legal cannabis commerce worldwide. The firm was ranked as the fourth-largest craft brewer in the US and the biggest cannabis company in Canada based on revenue. Canaccord attributed its Hold rating to a challenging beer market.

Following Tilray Brands, Inc. (NASDAQ:TLRY)’s second-quarter results, Roth Capital retained its Neutral rating. It trimmed its price objective to $10 from $20 on January 20, 2026. The company cited CC Pharma’s inflection, Canadian adult-use results, and foreign sales as signals of growing momentum. As stated by Roth, the firm’s future depends on the results of US legislation. The analyst also mentioned the corporation’s vulnerability to intoxicating hemp products, which, if not addressed, may result in a prohibition on November 13, 2026.

Tilray Brands, Inc. (NASDAQ:TLRY) is a consumer packaged goods firm that specializes in the production, processing, and marketing of cannabis products globally, as well as medicinal cannabis research. It operates in four segments: cannabis, distribution, beverage, and wellness.

1. Cronos Group Inc. (NASDAQ:CRON)

Number of Hedge Fund Holders: 16

Analysts’ Upside Potential as of February 10: 2.27%  

Cronos Group Inc. (NASDAQ:CRON) is among the Best Marijuana Stocks. 

Canaccord analyst Kenric Tyghe started covering Cronos Group Inc. (NASDAQ:CRON) with a Buy rating and a C$4.25 price target, as reported by The Fly on January 27, 2026. According to the analyst, the corporation’s two biggest markets at the moment are Canada and Israel. Tyghe noted that the Canadian cannabis company’s latest acquisition of CanAdelaar and the growth of the corporation are at the forefront of revolutionary development.

Cronos Group Inc. (NASDAQ:CRON) expanded its cross-border product strategy by launching its premium Lord Jones cannabis brand in Israel on February 2, 2026. Five indoor-grown flower strains for medical patients are part of the initial launch. According to the corporation, Israel is a crucial market for expanding its brand internationally. The production process for Lord Jones products includes glass jar packing, cold curing, hand trimming, small-batch indoor growing, selected genetics, and thorough testing. As stated by the firm, products are sold in pharmacies all around Israel, and limited-edition and special edition products will be added in the future.

Cronos Group Inc. (NASDAQ:CRON) is a cannabis manufacturer and distributor. It functions through the Israel and Canada divisions.

While we acknowledge the potential of CRON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRON and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None.  7 Best Cannabis Stocks to Invest In Now is originally published on Insider Monkey. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.